Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 3/20 | 0.42 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.40 |
| ▸ | GLA known ✓ | P06280 | 2/20 | 0.38 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.38 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | CYCS | P99999 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358276 | 0.99 | TOP1 (0.43) | KDM4EKMT2AALDH1A1HPGDTOP1 | |
| SCHEMBL140683 | 0.99 | TOP1 (0.43) | KDM4EKMT2AALDH1A1HPGDTOP1 | |
| SCHEMBL29062055 | 0.97 | TOP1 (0.42) | KDM4EKMT2AALDH1A1HPGDTOP1 | |
| SCHEMBL28351380 | 0.97 | TOP1 (0.42) | KDM4EKMT2AALDH1A1HPGDTOP1 | |
| SCHEMBL28927048 | 0.97 | TOP1 (0.42) | KDM4EKMT2AALDH1A1HPGDTOP1 | |
| SCHEMBL30632112 | 0.97 | TOP1 (0.42) | KDM4EKMT2AALDH1A1HPGDTOP1 | |
| SCHEMBL11341449 | 0.97 | TOP1 (0.42) | KDM4EKMT2AALDH1A1HPGDTOP1 | |
| SCHEMBL11293563 | 0.97 | TOP1 (0.42) | KDM4EKMT2AALDH1A1HPGDTOP1 | |
| SCHEMBL28650010 | 0.97 | TOP1 (0.42) | KDM4EKMT2AALDH1A1HPGDTOP1 | |
| SCHEMBL28492100 | 0.97 | TOP1 (0.42) | KDM4EKMT2AALDH1A1HPGDTOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240172755-A1 | USE OF PORPHYRIN NANOSTRUCTURES AS ANTIMICROBIAL AGENTS | LUNANO INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240148749-A1 | MNTBAP AND M(III)N-SUBSTITUTED PYRIDYLPORPHYRINS(MNPS)FOR USE IN REVERSING SEPSIS-INDUCED MICROGLIAL CELLS ALTERATIONS AND/OR FOR TREATING SEPSIS OR SEPSIS-ASSOCIATED ENCEPHALOPATHY | PASTEUR INSTITUT (FR) | 2024-05-09 | — | — | US | disclosed |
| EP-4308107-A1 | MNTBAP AND M(III)N-SUBSTITUTED PYRIDYLPORPHYRINS(MNPS)FOR USE IN REVERSING SEPSIS-INDUCED MICROGLIAL CELLS ALTERATIONS AND/OR FOR TREATING SEPSIS OR SEPSIS-ASSOCIATED ENCEPHALOPATHY | INSTITUT PASTEUR (FR) | 2024-01-24 | — | — | EP | disclosed |
| CN-115501335-B | Preparation method and application of photoacoustic enhanced multiple enzyme activity nano enzyme hydrogel | 昆明理工大学 | 2023-12-08 | — | — | CN | disclosed |
| CN-113651514-B | Substrate modifier for submerged ecological restoration and preparation method thereof | 广州和源生态科技发展股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-115501335-A | Preparation method and application of photo-acoustic enhanced multi-enzyme activity nano-enzyme hydrogel | 昆明理工大学 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022204074-A1 | USE OF PORPHYRIN NANOSTRUCTURES AS ANTIMICROBIAL AGENTS | LUNANO INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-11287433-B2 | Methods for in vitro investigating mitochondrial replication dysfunction in a biological sample, kits and uses thereof, therapeutic methods against progeroid-like syndromes or symptoms and screening method for identifying particular protease inhibitor(s) and/or nitroso-redox stress scavenger compound(s) | INSTITUT PASTEUR (FR) | 2022-03-29 | — | — | US | disclosed |
| CN-113651514-A | Substrate modifier for submerged ecological restoration and preparation method thereof | 广州和源生态科技发展股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| EP-3105596-B1 | METHODS FOR IN VITRO INVESTIGATING MITOCHONDRIAL REPLICATION DYSFUNCTION IN A BIOLOGICAL SAMPLE, KITS AND USES THEREOF, THERAPEUTIC METHODS AGAINST PROGEROID-LIKE SYNDROMES OR SYMPTOMES AND SCREENING METHOD FOR IDENTIFYING PARTICULAR PROTEASE INHIBITOR(S) AND/OR NITROSO-REDOX STRESS SCAVENGER COMPOUND(S) | PASTEUR INSTITUT (FR) | 2020-05-27 | — | — | EP | disclosed |
| US-20200049718-A1 | METHODS FOR IN VITRO INVESTIGATING MITOCHONDRIAL REPLICATION DYSFUNCTION IN A BIOLOGICAL SAMPLE, KITS AND USES THEREOF, THERAPEUTIC METHODS AGAINST PROGEROID-LIKE SYNDROMES OR SYMPTOMES AND SCREENING METHOD FOR IDENTIFYING PARTICULAR PROTEASE INHIBITOR(S) AND/OR NITROSO-REDOX STRESS SCAVENGER COMPOUND(S) | PASTEUR INSTITUT (FR) | 2020-02-13 | — | — | US | disclosed |
| US-10338082-B2 | Methods for in vitro investigating mitochondrial replication dysfunction in a biological sample, kits and uses thereof, therapeutic methods against progeroid-like syndromes or symptomes and screening method for identifying particular protease inhibitor(s) and/or nitroso-redox stress scavenger compound(s) | INSTITUT PASTEUR (FR) | 2019-07-02 | — | — | US | disclosed |
| US-20170242034-A1 | METHODS FOR IN VITRO INVESTIGATING MITOCHONDRIAL REPLICATION DYSFUNCTION IN A BIOLOGICAL SAMPLE, KITS AND USES THEREOF, THERAPEUTIC METHODS AGAINST PROGEROID-LIKE SYNDROMES OR SYMPTOMES AND SCREENING METHOD FOR IDENTIFYING PARTICULAR PROTEASE INHIBITOR(S) AND/OR NITROSO-REDOX STRESS SCAVENGER COMPOUND(S) | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2017-08-24 | — | — | US | disclosed |
| EP-3105596-A1 | METHODS FOR IN VITRO INVESTIGATING MITOCHONDRIAL REPLICATION DYSFUNCTION IN A BIOLOGICAL SAMPLE, KITS AND USES THEREOF, THERAPEUTIC METHODS AGAINST PROGEROID-LIKE SYNDROMES OR SYMPTOMES AND SCREENING METHOD FOR IDENTIFYING PARTICULAR PROTEASE INHIBITOR(S) AND/OR NITROSO-REDOX STRESS SCAVENGER COMPOUND(S) | Institut Pasteur (FR) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015121459-A1 | METHODS FOR IN VITRO INVESTIGATING MITOCHONDRIAL REPLICATION DYSFUNCTION IN A BIOLOGICAL SAMPLE, KITS AND USES THEREOF, THERAPEUTIC METHODS AGAINST PROGEROID-LIKE SYNDROMES OR SYMPTOMES AND SCREENING METHOD FOR IDENTIFYING PARTICULAR PROTEASE INHIBITOR(S) AND/OR NITROSO-REDOX STRESS SCAVENGER COMPOUND(S) | INSTITUT PASTEUR (FR) | 2015-08-20 | — | — | WO | disclosed |
| EP-2908137-A1 | Methods for in vitro investigating mitochondrial replication dysfunction in a biological sample, kits and uses thereof, therapeutic methods against progeroid-like syndromes or symptomes and screening method for identifying particular protease inhibitor(s) and/or nitroso-redox stress scavenger compound(s) | INSTITUT PASTEUR (FR) | 2015-08-19 | — | — | EP | disclosed |
| US-8871926-B1 | Synthesis of porphyrin nanostructures | SANDIA CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148749-A1 | MNTBAP AND M(III)N-SUBSTITUTED PYRIDYLPORPHYRINS(MNPS)FOR USE IN REVERSING SEPSIS-INDUCED MICROGLIAL CELLS ALTERATIONS AND/OR FOR TREATING SEPSIS OR SEPSIS-ASSOCIATED ENCEPHALOPATHY | PEBP1, TPX2, MPEG1 | TOP1 3489/4885MMP8 2401/4885MMP13 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.